The availability of novel anti-GREM1 pharmaceutics should expand and improve the treatment options for clinicians aiming not only to kill cancer cells and reduce tumor burden, but also to specifically target CSCs and lower the cancer recurrence risk. This evidence concerns the gene GREM1 and neoplasm.